Core Viewpoint - EverGen Infrastructure Corp. has entered into a 20-year Biomethane Purchase Agreement with FortisBC Energy Inc. for the purchase of Renewable Natural Gas produced at its Fraser Valley Biogas facility, marking a significant step in supporting renewable energy initiatives and reducing greenhouse gas emissions [1][2]. Group 1: Agreement Details - The Biomethane Purchase Agreement (BPA) allows FortisBC to purchase Renewable Natural Gas (RNG) from Fraser Valley Biogas Ltd. (FVB) for integration into its natural gas system, which will help reduce reliance on conventional natural gas and lower greenhouse gas emissions [2][3]. - This agreement provides EverGen with a long-term, contracted revenue stream and supports FortisBC's commitment to a renewable and lower carbon gas supply [2][3]. Group 2: Company Background - Fraser Valley Biogas, a wholly owned subsidiary of EverGen, is recognized as the original RNG project in Western Canada and the first to inject RNG into FortisBC's network, utilizing anaerobic digestion and biogas upgrading processes [4]. - The facility not only produces RNG but also generates organic liquid fertilizer from agricultural waste, contributing to sustainable farming practices in the region [4]. Group 3: Company Mission and Growth - EverGen Infrastructure Corp. is positioned as Canada's Renewable Natural Gas Infrastructure Platform, focusing on combating climate change and promoting sustainable energy solutions [5]. - The company is an independent renewable energy producer with plans for continued growth across North America, emphasizing the development and operation of renewable energy projects [5].

Core Viewpoint - EverGen Infrastructure Corp. has successfully closed a $13.0 million asset-level debt facility with Farm Credit Canada, which will support its subsidiary Fraser Valley Biogas Ltd. [1] Financial Developments - The company has repaid the majority of its corporate debt facility, indicating a strengthening financial position [1] - The closing of the second tranche of its previously announced non-brokered private placement is also highlighted, suggesting ongoing capital-raising efforts [1]

Core Viewpoint - EverGen Infrastructure Corp. is advancing its debt refinancing and private placement initiatives, which are expected to strengthen its financial position and support growth in 2026 [2][3]. Debt Refinancing Activities - EverGen has executed a letter of intent for a $13 million asset-level debt facility aimed at repaying a majority of its corporate debt, with terms aligned to its current operations [2]. - The company has entered into a Credit Agreement with Farm Credit Canada for a $13 million term loan and a $250,000 operating line of credit, with closing expected soon [3]. Private Placement Update - The second tranche of a non-brokered private placement is being extended for up to 11,666,667 common shares, aiming for gross proceeds of up to $7 million at a price of $0.60 per share [4]. - The first tranche closed on May 21, 2025, raising $5 million through the issuance of 8,333,333 common shares [4]. - The second tranche is expected to close soon, with proceeds primarily allocated for debt repayment and working capital [5]. Company Overview - EverGen Infrastructure Corp. is a Canadian renewable natural gas infrastructure platform focused on combating climate change and promoting sustainability [6]. - The company operates a portfolio of renewable energy projects and is expected to continue its growth across North America [6].

REHOVOT, Israel and BOSTON, January 7, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicineâ"¢ platform. This partnership aims to accelerate the discov ...

Group 1 - The Annual General and Special Meeting of EverGen Infrastructure Corp. is being held both in person and via video conference [2][4] - The meeting is chaired by the CEO of EverGen, Chase Edgelow, who also introduced the directors and officers present [1][2] - A brief corporate update will follow the formal meeting, with a more comprehensive update planned for the coming weeks [3] Group 2 - The meeting will include a report from the scrutineer on the shareholders present, both in person and by proxy, as well as the results of any ballots or polls [4]

Core Insights - Evogene Ltd. is focusing on computational chemistry and the generative design of small molecules for pharmaceuticals and agriculture, with a strategic emphasis on its AI-driven platform, ChemPass AI [1] Financial Performance - On November 20, 2025, Evogene reported earnings per share of $0.44, exceeding the estimated loss of $0.41 per share [2][5] - The company generated revenue of $312,000, which was below the estimated $650,000, indicating challenges in meeting market expectations [2][5] Valuation Metrics - The price-to-sales ratio is approximately 1.40, indicating that investors are willing to pay $1.40 for every dollar of sales, reflecting confidence in Evogene's potential [3] - The enterprise value to sales ratio stands at about 2.04, showing the company's valuation relative to its sales [3] - The enterprise value to operating cash flow ratio is around -0.78, suggesting difficulties in generating positive cash flow from operations [3] Liquidity and Debt Position - Evogene's debt-to-equity ratio is approximately -3.57, indicating more liabilities than equity [4] - The current ratio is about 1.89, suggesting a relatively healthy liquidity position that allows the company to cover its short-term obligations [4]

Core Insights - EverGen Infrastructure Corp. reported its Q3 2025 financial results, highlighting a record in RNG production and ongoing optimization efforts across its facilities [2][5]. Financial Performance - Revenue for Q3 2025 was CAD 2.81 million, a decrease of 22% from CAD 3.60 million in Q3 2024 [4]. - The net loss increased to CAD 1.11 million in Q3 2025 from CAD 0.47 million in Q3 2024, marking a 134% rise [4][8]. - Adjusted EBITDA for Q3 2025 was CAD 0.47 million, down 52% from CAD 0.98 million in the same period last year [4][9]. - Total assets decreased by 16% to CAD 76.54 million from CAD 91.64 million year-over-year [4]. Operational Highlights - RNG production reached a new quarterly record, with total production of 51,770 gigajoules in Q3 2025, an increase of 27% compared to 40,674 gigajoules in Q3 2024 [4][7]. - The FVB facility set a new monthly RNG production record of over 13,000 gigajoules in September 2025 [3][5]. - Incoming organic feedstock decreased by 40% to 15,310 tonnes compared to 25,555 tonnes in Q3 2024 [4]. Strategic Developments - The PCR RNG Expansion project received regulatory support from Abbotsford City Council in July 2025, marking a key milestone [5][10]. - The company is advancing refinancing efforts, targeting a CAD 13 million debt facility to close in Q4 2025, along with an additional private placement of up to CAD 2 million [11]

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from $4 million in the same period last year, primarily due to lower revenue from AgPlenus activity [9][31] - Total operating loss for the nine months of 2025 was approximately $8.8 million, significantly reduced from approximately $15.3 million in the same period of 2024, mainly due to decreased operating expenses [10][35] - The net loss for the nine months of 2025 was approximately $2.5 million, compared to approximately $18 million in the same period last year, reflecting a $15.5 million decrease primarily due to reduced operating expenses and income from discontinued operations [37][38] Business Line Data and Key Metrics Changes - Lavie Bio's financial results are presented as a single line item in Evogene's consolidated P&L statement, reflecting the sale of the majority of its activities to ICL, which generated income of approximately $7.9 million in Q3 2025 [9][29] - Research and development expenses for the nine months of 2025 were approximately $6.2 million, down from $9.8 million in the same period of 2024, attributed to reduced R&D expenses in Biomica and the cessation of Canonic's operations [31][32] - Sales and marketing expenses for the nine months of 2025 totaled approximately $1.2 million, a decrease from approximately $1.6 million in the same period last year, mainly due to personnel cost reductions [10][32] Market Data and Key Metrics Changes - The global agricultural market was valued at $79 billion in 2024, with significant opportunities for new product development in herbicides, insecticides, and fungicides [21] - The pharmaceutical market for small molecule-based drugs is valued at approximately $780 billion, representing nearly 60% of the global pharmaceutical market [24] Company Strategy and Development Direction - The company is transitioning to focus on computational chemistry, particularly in the generative design of small molecules for the pharmaceutical and agriculture industries [7][27] - The strategy includes leveraging the proprietary generative AI tech engine, Campus AI, to design novel small molecules that meet multiple parameters for commercial success [18][27] - The company aims to strengthen collaborations with leading global companies in both the agriculture and pharmaceutical sectors to drive innovation and product development [20][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increased interest in AI-driven drug discovery following recent partnerships in the industry, indicating a positive outlook for Evogene's technology [41][42] - The company expects to announce additional collaborations with biotech companies and academic institutions in the near future, aiming to enhance its market position [46][50] - Management expressed confidence in the potential for success in the pharmaceutical sector, emphasizing the unique capabilities of their team and technology [56][57] Other Important Information - The company completed a cost reduction plan by the end of Q2 2025, which is reflected in the reduced operating expenses in Q3 2025 [8][29] - The cash balance as of September 30, 2025, was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets [10][30] Q&A Session Summary Question: Has the levels of interest in AI champs increased post the recent NVIDIA Eli Lilly AI drug discovery partnerships? - Management noted that the announcement increased interest in AI-related companies in the pharma industry, and Evogene has seen growing interest in its technology [41][42] Question: How close are you to unlocking partners with AI champs? - Management indicated an increase in potential candidates for collaboration and expects to announce new partnerships with biotech companies early next year [45][46] Question: What is the IR strategy going forward? - Management confirmed plans to initiate roadshows and participate in conferences to enhance awareness of the company's new strategy and technology [47][49] Question: Could you highlight upcoming catalysts over the coming 6-12 months? - Management outlined expectations for new collaborations in both the pharma and ag divisions, as well as potential announcements regarding partnerships with major tech companies [50][51] Question: What type of revenue level can we expect for customer seeds in Q4 and for 2026? - Management refrained from disclosing specific revenue levels but mentioned ongoing discussions with strategic companies that could significantly impact future revenue [52][53] Question: How excited are you about AI champs compared to all your other times at Evogene? - Management expressed optimism about the focus on the pharma industry and the potential for significant financial rewards from successful collaborations [54][56]

Financial Data and Key Metrics Changes - For the nine months ending September 30, 2025, revenues were approximately $3.5 million, a decrease from approximately $4 million in the same period last year, primarily due to lower revenue from AgPlenus activity [9][31] - Total operating loss for the nine months of 2025 was approximately $8.8 million, a significant decrease from approximately $15.3 million in the same period of the previous year, mainly due to reduced operating expenses [10][35] - The net loss for the nine months of 2025 was approximately $2.5 million compared to approximately $18 million in the same period last year, reflecting a $15.5 million decrease primarily due to decreased operating expenses and income from discontinued operations [37][38] Business Line Data and Key Metrics Changes - The financial results of Lavie Bio, Evogene's subsidiary, are presented as a single line item in the consolidated P&L statement for 2025, reflecting the sale of the majority of its activities to ICL [8][29] - Research and development expenses for the nine months of 2025 were approximately $6.2 million, a decrease of approximately $3.6 million compared to $9.8 million in the nine months of 2024, primarily due to reduced R&D expenses in Biomica and the cessation of Canonic's operations [31][32] - Sales and marketing expenses for the nine months of 2025 were approximately $1.2 million, a decrease of approximately $400,000 compared to approximately $1.6 million in the same period last year, mainly due to personnel cost reductions [10][32] Market Data and Key Metrics Changes - The global agricultural market was valued at $79 billion in 2024, with significant opportunities for new product development in herbicides, insecticides, and fungicides [21] - The global pharmaceutical market for small molecule-based drugs is valued at approximately $780 billion, representing nearly 60% of the market [23] Company Strategy and Development Direction - The company is transitioning to focus on computational chemistry and generative design of small molecules for the pharmaceutical and agriculture industries [6][7] - The strategy includes leveraging the proprietary generative AI tech engine, Campus AI, to design novel small molecules that meet multiple parameters for commercial success [12][18] - The company aims to strengthen collaborations with leading global companies in both agriculture and pharmaceuticals to drive innovation and product development [28][25] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increased interest in AI-driven drug discovery following recent partnerships in the industry, indicating a positive outlook for Evogene's technology [39][40] - The company expects to announce additional collaborations in the pharma division and expand existing partnerships in agriculture, which are anticipated to generate cash inflows [47][48] Other Important Information - The company completed a cost reduction plan, which is reflected in the reduced operating expenses for the third quarter of 2025 [8][29] - The cash balance as of September 30, 2025, was approximately $16 million, reflecting proceeds from the sale of Lavie Bio's assets [10][30] Q&A Session Summary Question: Has the levels of interest in AI champs increased post the recent NVIDIA Eli Lilly AI drug discovery partnerships? - Management noted that the announcement increased interest in AI-related activities in the pharma industry, and they have seen growing interest in their technology [39][40] Question: How close are you to unlocking partners with AI champs? - Management indicated that interest has increased significantly, and they expect to announce new collaborations with biotech companies early next year [43][44] Question: What is the IR strategy going forward? - Management confirmed that they will focus on presenting the new company strategy and will initiate roadshows and participate in conferences to increase visibility [45][46] Question: Could you highlight upcoming catalysts over the coming 6-12 months? - Management expects to announce new collaborations in both the pharma and ag divisions, as well as additional partnerships with major tech companies [47] Question: What type of revenue level can we expect for customer seeds in Q4 and for 2026? - Management refrained from disclosing specific revenue levels but mentioned ongoing discussions with strategic companies that could significantly impact future revenue [48] Question: How excited are you about AI champs compared to all your other times at Evogene? - Management expressed optimism about the focus on the pharma industry, highlighting the unique expertise of their team and the potential for significant financial rewards [49][50]

Core Insights - Casterra Ag Ltd. and Fantini Italia S.R.L. have announced a strategic collaboration aimed at large-scale commercial castor cultivation through advanced mechanization technologies, addressing the rising global demand for castor oil used in biofuels and bio-based industrial products [1][2][4] Industry Overview - The global castor oil and derivatives market is valued at approximately USD 2.4 billion and is projected to reach USD 3.09 billion by 2030, growing at a CAGR of 5.20% [3] Company Collaboration - The partnership between Casterra and Fantini focuses on integrating high-yield castor varieties with advanced harvesting and threshing technologies, aiming to modernize castor farming and support industrial-scale production [4][5] - Casterra's high-yield castor varieties are designed for industrial-scale cultivation and are compatible with Fantini's precision harvesting technologies, facilitating tailored solutions for various geographical markets [4][5] Environmental Commitment - Both companies emphasize their commitment to sustainability, with Fantini's machinery reportedly reducing carbon footprint by about two-thirds compared to conventional solutions [5][10]